Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Genitourinary 1

Conditions

Breast Neoplasms 232Carcinoma, Non-Small-Cell Lung 229Prostatic Neoplasms 168Multiple Myeloma 155Neoplasms 132Colorectal Neoplasms 123Leukemia, Myeloid, Acute 122Lung Neoplasms 112Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 91Carcinoma, Hepatocellular 90Melanoma 87Lymphoma 84Triple Negative Breast Neoplasms 76Pancreatic Neoplasms 75Ovarian Neoplasms 71Sarcoma 67Lymphoma, Large B-Cell, Diffuse 66Carcinoma, Renal Cell 64Brain Neoplasms 63Recurrence 62Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Head and Neck Neoplasms 57Leukemia, Lymphocytic, Chronic, B-Cell 56Lymphoma, Non-Hodgkin 53Urinary Bladder Neoplasms 52Stomach Neoplasms 52Hematologic Neoplasms 52Rectal Neoplasms 49Small Cell Lung Carcinoma 48

Interventions

cabozantinib 1Random Allocation 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoid Tumor × 90 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡